NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
This article was originally published in The Pink Sheet Daily
Executive Summary
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.